Bristol Myers Squibb’s COBENFY has received FDA approval for treating adult schizophrenia. As a first-of-its-kind medication, COBENFY adopts a novel pharmacological approach by targeting brain receptors M1 and M4, breaking away from the current therapeutic paradigm.
COBENFY’s approval stems from the EMERGENT clinical program, which yielded positive results. In two Phase 3 trials (EMERGENT-2 and EMERGENT-3), COBENFY significantly reduced schizophrenia symptoms. It achieved a 9.6-point and 8.4-point reduction in PANSS scores compared to placebo.
COBENFY’s safety and tolerability have been established through acute and long-term trials. After more than three decades without a new class of medication for schizophrenia, COBENFY represents a groundbreaking advancement. It offers an alternative treatment option for individuals who experience inadequate symptom control or side effects with current therapies.
Dr. Chris Boerner, CEO of Bristol Myers Squibb, emphasized the milestone of introducing a completely new pharmacological approach to schizophrenia, aiming to reshape the treatment landscape. The medication’s approval marks a significant step in the company’s re-entry into neuropsychiatry.
Schizophrenia affects approximately 2.8 million people in the United States, with symptoms typically emerging in early adulthood. Despite existing treatments, many patients experience persistent symptoms or side effects. COBENFY’s availability expands treatment options and provides hope for individuals seeking effective symptom management.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
